News | March 03, 2024
Briefs: SMS Pharmaceuticals and Vimta Labs
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
With this, the company can start selling Ibuprofen in the European markets.
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
The company posted net profit of Rs.7.61 crores for the period ended December 31, 2019.
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)